SymphonyAI and AML Intelligence Launch FinCrime Frontier 2025–26 Report: Proactive Intelligence Becomes Compliance’s Next Competitive Edge
11.11.2025 10:00:00 CET | Business Wire | Press Release
SymphonyAI, a global leader in vertical AI product platforms, and AML Intelligence, the leading source of news and insight for the financial crime compliance community, today released the FinCrime Frontier 2025–26 Report. The landmark study defies conventional industry narratives: rather than seeing evolving compliance expectations as a burden, a majority of financial institutions now cite them as the primary opportunity and catalyst for modernization.
A sector ready for transformation - if it can break through real dependencies
Insights from over 250 compliance, risk, and financial crime leaders show a pivotal mindset shift. Instead of bracing for disruption, 58% of institutions say today’s fast-changing environment is the push they need to invest in proactive intelligence and smarter, data-driven operations. Ambition is high: nearly 80% plan to implement AI-driven compliance solutions within 18 months, and most expect measurable ROI in core areas like transaction monitoring and customer due diligence within two years.
Yet, the report also uncovers the hard limits threatening to slow this transformation:
- Only 11% of respondents are “very confident” in their data quality, with over half admitting to significant fragmentation or gaps - making the move to intelligence-led compliance a steeper hill to climb.
- 46% of compliance leaders cite cost and data quality as the top barriers to scaling automation and AI - outstripping fears of cultural resistance or skills shortages.
- Automation is advancing, but not fast enough: over 70% of organizations say less than half of their AML activities are automated, with many still bogged down by manual reviews and high false positive rates.
- Responsible AI governance and performance measurement lag ambition: only 17% of institutions have fully operational AI governance frameworks in place, and nearly three-quarters have never calculated ROI on their technology investments.
Together, these findings show a sector ready to move from isolated AI projects to connected, end-to-end compliance systems—where data, automation, and human expertise work in concert to create true proactive intelligence.
Jason Shane, Head of Product Strategy and Innovation at SymphonyAI, said: “Institutions are no longer waiting for the next shoe to drop – they’re seeing changing compliance expectations as their opening to build intelligence and resilience into the heart of their operations. Our research shows that success now depends on unifying data, automating the entire compliance lifecycle, and embedding explainable AI into day-to-day decision-making. The front-runners will be those that make proactive intelligence real by moving toward end-to-end compliance systems that connect data, automation, and human expertise in one continuous flow.”
Stephen Rae, Co-Founder and Chair of AML Intelligence, commented: “At AML Intelligence, we’re proud to partner with SymphonyAI to deliver data-driven insights that can support regulators, financial institutions, and compliance leaders across the globe. This report not only surfaces the challenges facing our industry - it highlights where real progress is being made. It is clear that intelligent technologies, used responsibly, will define the next era of financial crime prevention.”
The FinCrime Frontier 2025-26 Report underscores why proactive intelligence is fast becoming the organizing principle for next-generation compliance—one built on connected data, continuous automation, and human-AI partnership across banking, insurance, and financial services.
Read the full report here:https://www.symphonyai.com/resources/analyst-report/financial-services/fincrime-frontier-2025-26-report/
About SymphonyAI
SymphonyAI delivers Vertical AI product platforms that help enterprises solve their most complex, high-value challenges — from stopping financial crime to improving store -performance and boosting manufacturing efficiency. Trusted by more than 2,000 enterprise customers worldwide, including 200 of the top financial institutions, the top 25 CPG companies, and many of the world’s largest grocers and industrial manufacturers, SymphonyAI provides domain-trained applications and pre-built agents that are ready to work on day one. Learn more at https://www.symphonyai.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251111063481/en/
Contacts
Media Contact
SymphonyAI
Media@symphonyai.com
Treble -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftreblepr.com&e
sheet=54355670&newsitemid=20251111063481&lan=en-US&anchor=Treble&index=6&md5=64f
ed30f1ce8b7c41188173385ae045a
Sarah Vandiver
symphonyai@treblepr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom